Meritage Homes
MTH
Apple
AAPL
Taylor Morrison Home
TMHC
4
KB Home
KBH
5
Toll Brothers
TOL
No Data
Earnings Preview: VRTX to Report Financial Results Post-market on February 12
Dr. Oz Is Fighting an Uphill Battle to Sell Congress on Trump's Healthcare Plan -- WSJ
These Are The Worst 25 Stocks to Own in February
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $606
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Brookdale Senior Living (BKD)
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager